Upcoming Anticipated Milestones: Hematologic Malignancies Program: Expects to enroll patients in all three arms in the Phase 1 umbrella trial for TSC-100 and TSC-101 and start reporting preliminary safety and biomarker data mid-year 2023. Expects to reach the recommended Phase 2 dose for TSC-100 and TSC-101 and report interim clinical data for the program by the end of 2023. The Company expects to report prevention of relapse data in 2024. Solid Tumor Program: Anticipate further expansion of the ImmunoBank by filing INDs for four TCRs throughout 2023. Anticipate sharing preliminary safety and biomarker data for the most advanced TCRs by the end of 2023. The Company expects to report initial multiplex therapy data for its first combination of TCRs under T-Plex in the first half of 2024.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TCRX:
- TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones
- TScan Therapeutics Announces Presentation at the H.C. Wainwright Cell Therapy Virtual Conference
- TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors
- TScan Therapeutics announces FDA clearance of three IND applications
